THE COURSE OF PREGNANCY IN WOMEN WITH PREECLAMPSIA COMBINED WITH FETAL GROWTH RETARDATION

REIHANA S. HAJIYEVA; MATANAT S. MUSAYEVA; ZUMRUD F. MAHMEDBEYOVA

doi:10.52340/jecm.2023.05.32

THE COURSE OF PREGNANCY IN WOMEN WITH PREECLAMPSIA COMBINED WITH FETAL GROWTH RETARDATION

Authors

REIHANA S. HAJIYEVA
MATANAT S. MUSAYEVA
ZUMRUD F. MAHMEDBEYOVA

DOI:

https://doi.org/10.52340/jecm.2023.05.32

Keywords:

preeclampsia, fetal growth retardation, complications, umbilical cord artery

Abstract

In order to assess the course of pregnancy in women with diagnosed preeclampsia (PE) in combination with fetal growth retardation (FGR), 97 pregnant women (gestation period 20-32 weeks) with PE (average age 30.2±1.86 years) were examined, of which 48 women were with PE+FGR (main group), 49 women - with PE without FGR (comparison group). Age, gestational age, weight, parity, body mass index (BMI), the presence of somatic diseases were compared. A basic obstetric scan was performed and Dopplerography of the uterine and umbilical arteries was performed. Pregnant women aged 34-37 years were more likely to occur in the PE+FGR group (by 43.4%, p=0.068). In 12.5% of cases, women with PE+ FGR had a history of FGR more often (p=0.050). A significant difference was revealed in the average value of PI (1.48±0.23 and 0.92±0.12, respectively, in the main and comparative groups, p=0.033), RI (0.98±0.11 and 0.70±0.08, respectively, in the main and comparative groups, p=0.042) and S/D (3.38±0.10 and 2.90±0.22, respectively, in the main and the comparative group, p=0.050) in the umbilical artery. A frequent complication in both groups was placental insufficiency and the threat of premature birth. The incidence of acute respiratory diseases was 77.2% higher in patients with PE+FGR (p=0.028). The results of the study confirmed the importance of controlling fetal-placental blood flow.

Downloads

Download data is not yet available.

References

Adekanmi AJ, Roberts A, Morhason-Bello IO, Adeyinka AO. Utilization of uterine and umbilical artery Doppler in the second and third trimesters to predict adverse pregnancy outcomes: a Nigerian experience. Women's Health Report. 2022;3(1):256–266, doi: 10.1089/whr.2021.0058.

American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins. ACOG Practice Bulletin #202: gestational hypertension and preeclampsia. Obstet Gynecol 2019;133(1):e1–25.

Bramham K, Briley AL, et al. Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study. Am J Obstet Gynecol. 2011;204(6):512.

Gęca T, Stupak A, Nawrot R, et al. Placental proteome in late onset of fetal growth restriction. Mol Med Rep. 2022;26(6):356. doi: 10.3892/mmr.2022.12872.

Marasciulo F, Orabona R, Fratelli N, et al. Preeclampsia and late fetal growth restriction. Minerva Obstet Gynecol. 2021;73(4):435-441. doi: 10.23736/S2724-606X.21.04809-7.

Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Da Silva AB, Nicolaides KH. Screening for pre-eclampsia at 11-13 weeks’ gestation: Use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet. Gynecol. 2020;56:400–407. doi: org/10.1002/uog.22093.

Ortega MA, Fraile-Martínez O, García-Montero C, Sáez MA, et al. The Pivotal Role of the Placenta in Normal and Pathological Pregnancies: A Focus on Preeclampsia, Fetal Growth Restriction, and Maternal Chronic Venous Disease. Cells. 2022;11(3):568. doi: 10.3390/cells11030568.

Palma C, Jellins J, Lai A, Salas A, Campos A, Sharma S, et al. Extracellular Vesicles and Preeclampsia: Current Knowledge and Future Research Directions. Subcell Biochem. 2021;97:455-482.

Poon LC, Magee LA., Verlohren S, Shennan A, von Dadelszen P, Sheiner E, et al. A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia. Gynecology & Obstetrics. 2021;154(S1):3-31. doi: 10.1002/ijgo.13763.

Salomon LJ, Alfirevic Z, Da Silva Costa F, Deter RL, Figueras F, Ghi T, et al. ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth. Ultrasound in Obst and Gynecology. 2019;53(6):715-23

Schoots MH, Gordijn SJ, Scherjon SA, van Goor H, Hillebrands JL. Oxidative stress in placental pathology. Placenta. 2018;69:153-161. doi: 10.1016/j.placenta.2018.03.003.

Shakhbazova NA. Perinatal outcomes in cases with various methods of prevention of hypertensive disorders during pregnancy. Ros Vestn Perinatol i Pediatr 2018;63:(3):45–50 (in Russ).

Sharabi-Nov A, Tul N, Kumer K, Premru Sršen T, Fabjan Vodušek V, Fabjan T, et al. Biophysical Markers of Suspected Preeclampsia, Fetal Growth Restriction and The Two Combined—How Accurate They Are? Reprod. Med. 2022;3(2):62-84. doi: 10.3390/reprodmed3020007.

Sharma D, Sharma P, Shastri S. Genetic, metabolic and endocrineaspect of intrauterine growth restriction: an update. J MaternFetal Neonatal Med. 2017;30(19):2263–2275. doi: 10.1080/14767058.2016.1245285.

Surico D, Bordino V, Cantaluppi V, Mary D, Gentilli S, Oldani A, et al. Preeclampsia and intrauterine growth restriction: Role of human umbilical cord mesenchymal stem cells-trophoblast cross-talk. PLoS One. 2019;14(6):e0218437. doi: 10.1371/journal.pone.0218437.

Tan MY, Syngelaki A, Poon LC, Rolnik DL, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation. Ultrasound Obstet. Gynecol. 2018;52:186–195.

Zhu Y-Ch, Lin L, Li B-Y; Li X-T, Chen D-J, Zhao X-L, et al. Incidence and Clinical Features of Fetal Growth Restriction in 4 451 Women with Hypertensive Disorders of Pregnancy. Maternal-Fetal Medicine. 2020;2(4):207-210. doi: 10.1097/FM9.0000000000000062